NCT05681884 - Safety and Efficacy of Faricimab in Patients With NPDR | Biotech Hunter

Enrollment

179

Participants

Timeline

Start Date

May 16, 2023

Primary Completion Date

March 20, 2026

Study Completion Date

April 13, 2026

Conditions

Non-Proliferative Diabetic Retinopathy

Interventions

DRUG

Faricimab

Faricimab is a humanized bispecific antibody binding to human Ang-2 and VEGF. For Phase III studies, the Ro 686-7461 drug product is provided in single-dose 2-mL glass vials (6 mg/0.05 mL) with L-histidine/acetate buffered solution (approximately pH 5.5) containing sodium chloride, sucrose, L-methionine, polysorbate 20, and water for injection.

Trial Locations (16)

11590

Long Island Vitreoretinal Consultants, Westbury

27587

North Carolina Retina Associates, Wake Forest

29169

Palmetto Retina Center, West Columbia

29456

Charleston Neuroscience Institute, Ladson

32806

Florida Retina Institute, Orlando

34233

Retina Group of Florida, Sarasota

39202

Mississippi Retina Associates, Jackson

55416

Retina Consultants of Minnesota St. Louis Park, Saint Louis Park

77384

Retina Consultants of Texas, The Woodlands

77401

Retina Consultants of Texas, Bellaire

77494

Retina Consultants of Texas, Katy

77707

Retina Consultants of Texas, Beaumont

78240

Retina Consultants of Texas, San Antonio

78705

Austin Retina Associates, Austin

93309

California Retina Consultants, Bakersfield

95356

Retinal Consultants Medical Group, Modesto